Last reviewed · How we verify
NCT06056622
Motion Sickness Rehabilitation for Virtual Reality
NA trial testing Combined Exercises in Motion Sickness in 121 participants. Completed in 15 May 2023.
23 April 2023
Quick facts
| Lead sponsor | Abant Izzet Baysal University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 121 |
| Start date | 4 December 2022 |
| Primary completion | 23 April 2023 |
| Estimated completion | 15 May 2023 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Combined Exercises
- Placebo Exercise
Conditions studied
- Motion Sickness — all drugs for Motion Sickness →
Sponsor
Abant Izzet Baysal University
Who can join
Adults 18 to 80, any sex, with Motion Sickness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study was to investigate the effect of a rehabilitation program on motion sickness. A combined rehabilitation program will be given participants who showed motion sickness symptoms.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
An old approach to a novel problem: effect of combined balance therapy on virtual reality induced motion sickness: a randomized, placebo controlled, double-blinded study.
Ramazan K, Devran AY, Muhammed ON. · · 2024 · cited 2× · PMID 38374042 · DOI 10.1186/s12909-024-05152-4
Verify or expand the search:
- PubMed search for NCT06056622
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Combined Exercises
Trials testing the same drug.
- NCT05136573 — Exercises on CIPN, Fatigue, and Quality of Life in Colon Cancer Patients Receiving Chemotherapy · NA · unknown
Other recruiting trials for Motion Sickness
Currently open trials in the same condition.
- NCT06892340 — Evaluation of a Device to Reduce Motion Sickness and Spatial Disorientation · NA · recruiting
- NCT06138613 — Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness · Phase 3 · active not recruiting
- NCT05622344 — StableEyes With Active Neurofeedback · NA · recruiting
Other Abant Izzet Baysal University trials
Trials by the same sponsor.
- NCT07374744 — Effect of Interactive Video-Based Self-Management Education in Adults With Type 2 Diabetes · NA · not yet recruiting
- NCT07524790 — The Effect of Proprioceptive Neuromuscular Facilitation on Haemodynamic Responses in a Neurological Intensive Care · NA · not yet recruiting
- NCT07507721 — Tele-Nursing-Supported Mindfetalness: Anxiety and Prenatal Attachment · NA · not yet recruiting
- NCT07509021 — Neuropathic Pain, Catastrophizing, and Adherence in SAIS · recruiting
- NCT07535177 — Gas6 and Soluble MerTK in Periodontal Diseases · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06056622 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abant Izzet Baysal University
- Last refreshed: 28 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06056622.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing